CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ADAMANT Project seeks to develop advanced cancer therapies using monoclonal antibodies for targeted delivery of cytotoxic agents to tumors. The project emphasizes the discovery of tumor-associated antigens and aims to translate findings into clinical applications.
The selective delivery of bioactive agents (cytotoxics, radionuclides, cytokines) at the tumor site, while sparing normal tissues, represents one of the most promising avenues for the development of anticancer therapies with unprecedented efficacy and tolerability.
Monoclonal antibodies represent the preferred vehicle for the targeted delivery of bioactive agents to cancer sites, as they can display a preferential accumulation in primary and metastatic tumor lesions already few hours after intra…
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Zuerich
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, JENA
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, PULA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Switzerland, Otelfingen
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
